Industry landscapes
The companies, capital and talent shaping life sciences in Austin. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
20 of 258 tracked companies have open roles.
95 of 258 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 237 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 24.0% of disclosed capital, while 63.2% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $135.14M | 17 | 21 |
| 2017 | $77.01M | 10 | 16 |
| 2018 | $138.08M | 24 | 28 |
| 2019 | $292.74M | 16 | 22 |
| 2020 | $588.67M | 6 | 25 |
| 2021 | $317.74M | 6 | 20 |
| 2022 | $213.31M | 6 | 14 |
| 2023 | $158.76M | 6 | 15 |
| 2024 | $21.31M | 6 | 5 |
| 2025 | $408.56M | 2 | 15 |
Share of all disclosed company funding.
266 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by .
Backed by Justin Mateen and Mike Novogratz and others.
Backed by K1 Investment Management.
Participating investors were not recorded in this snapshot.
Backed by Redmile Group and Janus Henderson Investors and others.
Backed by F-Prime Capital and SV Angel and others.
Backed by Oceanpine Capital and Viva Biotech and others.
Backed by Remeditex and PTV Healthcare Capital and others.
Backed by Telegraph Hill Partners and Growth Capital Fund.
Participating investors were not recorded in this snapshot.
Participating investors were not recorded in this snapshot.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · company accounts; aggregate reporting threshold not met · 2 reporting entities from 10 eligible matches.
Sum of reporting-entity revenue; not Austin market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
None of 2 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 2 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Aspira Women's Health ↗926617 | $9.2m | $-12.8m | -138.7% | — | — |
| HeartSciences ↗1468492 | $0.0m | $-8.8m | -201499.5% | — | — |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the Austin companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
5 of the 258 companies on this page carry a measured traffic record (1.9%); these are the largest of those, by monthly visits. The median among them is 233,102 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Everlywelleverlywell.com | 502,873 | 62 | 65% |
| Heart Soilheartandsoil.co | 326,464 | 41 | 79.2% |
| Perfect Ketoperfectketo.com | 233,102 | 45 | 79.3% |
| Amy Myers MDamymyersmd.com | 80,433 | 43 | 52.4% |
| Season Healthseasonhealth.com | 50,196 | 38 | 71% |
Visits and authority are third-party web estimates, not company-reported figures.
10 of these companies (3.9%) publish at least one Android app — 127 apps in all, carrying 480.9K installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| PocketRxDigital Pharmacist | 284.3K | 4.5 | Health & Fitness |
| My Community PharmacyDigital Pharmacist | 49.3K | 4.5 | Health & Fitness |
| Embark VetEmbark Veterinary | 48.2K | 4.8 | Lifestyle |
| IQVIA ScribeAltavoz | 42.6K | 2.7 | Medical |
| Frontier XFourth Frontier | 10.5K | 4.4 | Health & Fitness |
| Quick Rx DrugsDigital Pharmacist | 4.9K | 4.5 | Health & Fitness |
| Season HealthSeason Health | 4.2K | 4.1 | Health & Fitness |
| NuCaraDigital Pharmacist | 2.4K | 4 | Health & Fitness |
| The Hometown PharmacyDigital Pharmacist | 1.7K | 4.5 | Health & Fitness |
| Heartland PharmacyDigital Pharmacist | 1.6K | 4.6 | Lifestyle |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q2–2026Q1).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Life Sciences Tech | 119 | 415.3K | PocketRx 284.3K | |
| Pharmacy It | 107 | 372.1K | My Community Pharmacy 49.3K | |
| Healthcare It | 4 | 11K | Frontier X 10.5K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 121 of 127 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
14 companies hiring · $3.04B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Homburger advised the shareholders of Swiss-based Clariness on the sale of 100% of their shares to SubjectWell.
Curative – $150.0M
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at $4.20 per share. In addition, in lieu of shares of common stock, Savara sold to certain investors that so chose, pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per pre-funded warrant. The aggregate gross proceeds to Savara from the offering were approximately $149.5 million before deducting underwriting discounts and commissions and other offering expenses.
On October 28, 2025, Genprex, Inc. announced a securities purchase agreement for a registered direct offering of 377,780 shares of common stock at $9.00 per share, expected to close on October 29, 2025. The offering includes a concurrent private placement of warrants for up to 755,560 shares, with potential gross proceeds of $6.6 million if fully exercised. The company plans to use the net proceeds, estimated at $3.0 million, for working capital and general corporate purposes.
ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune‑related diseases, today announced that it has entered into a securities purchase agreement for a private placement financing that is expected to result in total gross proceeds of up to approximately $103 million to Shattuck, before deducting placement agent fees and other private placement expenses.
Healthcare AI company Autonomize AI has closed a $28m Series A funding round, bringing its total raised to $32m.
Exo, a Silicon Valley-based medical imaging startup, is finalizing a funding round of up to $100 million to expand its AI-enhanced handheld ultrasound platform.
Phantom Neuro, the neurotech company advancing human-machine interfaces, today announced an oversubscribed $19 million Series A funding round led by Ottobock.
HealthTronics (Austin, Texas), a provider of urology services and products, reported that it has acquired Ocean Radiation Therapy (Daytona Beach, Florida), an entity that provides services to Atlantic Urological Associates' (AUA; also Daytona Beach) IGRT cancer treatment center.
Top 10 categories among 206 recorded events in the 24-month window.
6 companies with recorded IPO activity
Follow-on Offering · NASDAQ1 reports
IPO · NASDAQ6 reports
IPO · NASDAQ3 reports
Follow-on Offering1 reports
IPO3 reports
IPO1 reports
11 tracked people moves
Appointment Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR)
Appointment Chief Development Officer
Appointment Board of Directors
Appointment VP of Marketing
Appointment Chief Regulatory Officer
Appointment Member of the Board of Directors
Appointment Independent Director
Promotion Chief Medical Officer
1 recorded customer wins
Customer: Colgate-PalmoliveHealthcare
4 companies with reported reductions
73 rolescost reduction
33.0% rolescost reduction
Scale not stated roleswind down
30 rolesclinical program discontinuation
5 recorded events
U.S. Food and Drug Administration
submitted for 510(k) premarket clearanceU.S. Food and Drug Administration
pending FDA approvalU.S. Food and Drug Administration
trading haltedNasdaq
14 tracked suits
misleading securities statementsSecurities Fraud · Ongoing
merger enforcement / acquisition enjoinCivil · Filed
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| SubjectWell→clariness | Announced | 2026-02-11 | Not stated in snapshot |
| zimmer biomet→LDR ↗ | Completed | 2025-06-04 | Not stated in snapshot |
| Applied Biosystems Group→Ambion ↗ | Completed | 2025-02-14 | $35.0M |
| healthtronics→Endocare ↗ | Announced | 2025-02-14 | $16.0M |
| Luminex→Tm Bioscience | Announced | 2025-02-14 | Not stated in snapshot |
| Endocare→Cryomedical Sciences | Pending | 2025-02-14 | $2.2M |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
526 postings in the preceding 12 months. The full 1,039-posting snapshot covers 29 employers.
20 tracked postings mention remote work.
182 postings specify a level.
Top skills across 1,039 tracked postings in the available jobs snapshot.
Median across 30 postings with pay data, expressed in USD.
| Company | Employees |
|---|---|
| Curative ↗ | 2,251 |
| healthtronics ↗ | 500 |
| Signature Science ↗ | 235 |
| XBiotech ↗ | 169 |
| Embark Veterinary ↗ | 141 |
| L7 Informatics ↗ | 126 |
| Shattuck Labs ↗ | 89 |
| Aspira Women\'s Health ↗ | 85 |
152 founders and chief executives across 120 companies.
Pfizer Ex-GSK, Amgen, Avidia, Millennium Pharmaceuticals. Basel Institute for Immunology PhD 1991
Central Michigan University BS MBA, Michigan State University College of Law JD
CEO-Rein Therapeutics · Ex-Lung Therapeutics, TFF Pharmaceuticals, Enavail · The University of Texas at Austin BS 1996, PhD 2000
Ex- Luminex Corporation, Applied Research Labs. The University of Texas BS
Embark Veterinary, ex-Rue Gilt Groupe, ex-J Jill, Ohio State University - Fisher School of Business, 2001
Ex-Nano, Co-Founder JUCCCE, ex-The White House, Moxie Software, United States Department of Energy, TechNet, ROME…
Strategic Partner - Trinity Investors. The University of Texas at Austin Bachelor of Business Administration 2001
Ex-NantHealth, i2 Technologies. Texas A&M University 1988, University of Texas at Arlington PhD 1996
McMaster University. McGill University PhD 1994.
Ex-Amazon, Hubbard One. Northwestern University BS 2002
3D Bio Therapeutics, ex-Co-Founder Mycrobiomics, CEO Coronado Biosciences. University of Maryland BA 1975…
Ex-Boston Scientific, Accumed Systems. University of Colorado Boulder BA 1992, University of Michigan - Stephen M. Ross School of Business MBA 2002
17 profiles with education records.
4 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
2,271 articles in the measured 12-month window.
Life Sciences coverage tagged Austin · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 648 |
| 2021Q3 | 621 |
| 2021Q4 | 422 |
| 2022Q1 | 575 |
| 2022Q2 | 518 |
| 2022Q3 | 471 |
| 2022Q4 | 509 |
| 2023Q1 | 496 |
| 2023Q2 | 725 |
| 2023Q3 | 492 |
| 2023Q4 | 578 |
| 2024Q1 | 518 |
| 2024Q2 | 590 |
| 2024Q3 | 488 |
| 2024Q4 | 573 |
| 2025Q1 | 2,097 |
| 2025Q2 | 424 |
| 2025Q3 | 539 |
| 2025Q4 | 638 |
| 2026Q1 | 627 |
Article volume measures coverage, not market sales.
245 recorded company events across 35 companies; percentages use that event total.
Life Sciences coverage tagged Austin · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
United States comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| vaccine candidates | 3,157 | 898 | 252% |
| vaccine trials | 2,962 | 904 | 228% |
| vaccination campaigns | 2,752 | 555 | 396% |
| vaccine immunogenicity | 2,473 | 668 | 270% |
| mass vaccination sites | 2,021 | 272 | 643% |
| vaccination coverage | 1,516 | 202 | 650% |
| vaccine effectiveness study | 1,400 | 251 | 458% |
| angel investors | 1,344 | 590 | 128% |
| covid-19 vaccine development | 1,335 | 238 | 461% |
| pandemic vaccine stockpiling | 1,294 | 242 | 435% |
| investigational new vaccine | 451 | 1,069 | -58% |
| cell-based therapies | 619 | 1,059 | -42% |
| viral vector vaccines | 684 | 1,048 | -35% |
| cancer biomarkers | 670 | 1,040 | -36% |
| diagnostic biotechnology | 570 | 948 | -40% |
United States comparison coverage
core inflation rate, inflation outlook, inflation breakdown
52.8% critical · 34.6% positiveangel investors, vaccine candidates, vaccine trials
49.1% critical · 55.2% positivegdp acceleration, gdp growth rate, economic output growth
49.7% critical · 39.6% positiveLife Sciences coverage tagged Austin. Topic labels describe recorded classifications and can include broad context.
6,260 papers in the recorded india scope.
Tone counts: 5,526 positive · 456 neutral · 278 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: U1 snRNP regulates cancer cell migration and invasion in vitro
Common problems researchers identify · 0118.4% of this theme group
Researchers highlight technical hurdles in biochemical engineering, synthetic biology, and nanotechnology for biotech production.
Biochemical engineering (18) · Synthetic biology (12) · Biomanufacturing (8) · Nanotechnology (9)
Microbial Enzymes: Tools for Biotechnological Processes
Medical biofilms
| Year | Share index |
|---|---|
| 2022 | 67.9 |
| 2023 | 70.3 |
| 2024 | 84.4 |
| 2025 | 67.1 |
Common problems researchers identify · 0215.7% of this theme group
Papers flag rising public‑health threats from mycotoxins, pathogens, and contaminated food supplies.
Public health (15) · Mycotoxin (8) · Disease (12) · Contamination (8)
The growing burden of foodborne outbreaks due to contaminated fresh produce: risks and opportunities
A review of Listeria monocytogenes: An update on outbreaks, virulence, dose-response, ecology, and risk assessments
| Year | Share index |
|---|---|
| 2022 | 301.0 |
| 2023 | 265.8 |
| 2024 | 276.2 |
| 2025 | 304.0 |
Common problems researchers identify · 0315.5% of this theme group
Studies point to difficulties in interpreting mutations, DNA methylation, and metabolic pathways in oncology.
Mutation (7) · Cancer (9) · DNA methylation (5) · Gene (8)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine
| Year | Share index |
|---|---|
| 2022 | 974.1 |
| 2023 | 1199.2 |
| 2024 | 866.8 |
| 2025 | 797.1 |
Common problems researchers identify · 0415.2% of this theme group
Researchers discuss obstacles in engineering crops for drought, salinity, and other non‑biotic stresses.
Agriculture (33) · Abiotic stress (10) · Abiotic component (12) · Biotechnology (20)
Genetic Engineering for Modern Agriculture: Challenges and Perspectives
Phytohormones and their metabolic engineering for abiotic stress tolerance in crop plants
| Year | Share index |
|---|---|
| 2022 | 1472.5 |
| 2023 | 1503.8 |
| 2024 | 1656.9 |
| 2025 | 1839.0 |
Common problems researchers identify · 0514.7% of this theme group
Works identify problems in micronutrient production, biofortification, and fermentation‑based food improvements.
Micronutrient (9) · Production (13) · Nutrient (10) · Food science (7)
Improving nutrition through biofortification: A review of evidence from HarvestPlus, 2003 through 2016
Food fermentations: Microorganisms with technological beneficial use
| Year | Share index |
|---|---|
| 2022 | 120.6 |
| 2023 | 117.1 |
| 2024 | 113.1 |
| 2025 | 122.2 |
Common problems researchers identify · 0611.1% of this theme group
Papers emphasize the growing threat of antimicrobial resistance across clinical and environmental settings.
Antibiotic resistance (49) · Antimicrobial (31) · Antibiotics (22) · Drug resistance (8)
An overview of the antimicrobial resistance mechanisms of bacteria
The global threat of antimicrobial resistance: science for intervention
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.5% of this theme group
Studies reveal challenges in managing resistance among insects and pests threatening crops and health.
Resistance (14) · Insecticide resistance (5) · Vector (5) · Integrated pest management (5)
Insecticide Resistance in Mosquitoes: Impact, Mechanisms, and Research Directions
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
| Year | Share index |
|---|---|
| 2022 | 3.4 |
| 2023 | 3.1 |
| 2024 | 4.4 |
| 2025 | 4.3 |
Cautions · 0124.6% of this theme group
Researchers urge caution interpreting links between DNA repair mechanisms and mutation outcomes.
DNA repair (7) · DNA polymerase (6) · DNA damage (7) · Mutation (9)
Examining the link between chromosomal instability and aneuploidy in human cells
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
| Year | Share index |
|---|---|
| 2022 | 101.2 |
| 2023 | 139.0 |
| 2024 | 91.9 |
| 2025 | 79.2 |
Cautions · 0218.1% of this theme group
Works caution about unintended immune effects when targeting antibodies or cellular subsets.
Antibody (9) · In vivo (8) · Peripheral blood mononuclear cell (4) · Immune system (5)
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs
T cell responses towards PINK1 and ⍺-synuclein are elevated in prodromal Parkinson's disease - Fluorospot data
| Year | Share index |
|---|---|
| 2022 | 543.7 |
| 2023 | 602.0 |
| 2024 | 448.8 |
| 2025 | 441.1 |
Cautions · 0314.4% of this theme group
Papers warn of potential health impacts from nanomaterials and sugar‑related food safety issues.
Food safety (6) · Raw material (4) · Health benefits (4) · Sugar (3)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Soybean susceptibility to manufactured nanomaterials with evidence for food quality and soil fertility interruption
| Year | Share index |
|---|---|
| 2022 | 122.8 |
| 2023 | 120.4 |
| 2024 | 118.6 |
| 2025 | 154.1 |
Cautions · 0411.6% of this theme group
Studies caution that feed additives may affect animal performance and greenhouse‑gas emissions.
Dairy cattle (6) · Production (6) · Nutrient (6) · Beef cattle (5)
Impact of tannin-based additives on animal performance and enteric methane emissions in dairy and beef cattle: A meta-analysis
The effects of injectable trace mineral solutions on beef cattle performance and health during preconditioning and feedlot receiving: a syst
| Year | Share index |
|---|---|
| 2022 | 126.8 |
| 2023 | 122.4 |
| 2024 | 118.5 |
| 2025 | 129.2 |
Cautions · 0510.8% of this theme group
Researchers highlight uncertainties in applying genomic selection to improve crop and animal traits.
Gene (10) · Genomic selection (5) · Selection (6) · Trait (4)
Genomic Selection for Crop Improvement
Genomic selection in plant breeding: from theory to practice
| Year | Share index |
|---|---|
| 2022 | 2367.9 |
| 2023 | 2351.5 |
| 2024 | 2081.1 |
| 2025 | 1566.0 |
Cautions · 0610.5% of this theme group
Works advise careful evaluation of biological control and insecticide strategies to avoid resistance.
PEST analysis (9) · Agriculture (7) · Pest control (3) · Integrated pest management (3)
The use of fungal entomopathogens as endophytes in biological control: a review
Insecticide Control of Vector-Borne Diseases: When Is Insecticide Resistance a Problem?
| Year | Share index |
|---|---|
| 2022 | 1443.5 |
| 2023 | 1484.3 |
| 2024 | 1642.9 |
| 2025 | 1827.1 |
Cautions · 079.9% of this theme group
Papers caution that antibiotic practices in agriculture can propagate resistance to human pathogens.
Antibiotic resistance (12) · Antibiotics (9) · Antimicrobial (6) · Bacteria (5)
Multidrug evolutionary strategies to reverse antibiotic resistance
Impact of Antibiotic Use in Adult Dairy Cows on Antimicrobial Resistance of Veterinary and Human Pathogens: A Comprehensive Review
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Opportunities · 0119.6% of this theme group
Research explores beneficial microbes and their metabolites for improving human and animal health.
Antimicrobial (64) · Fermentation (55) · Bacteria (52) · Antibiotic resistance (37)
Probiotics, their health benefits and applications for developing healthier foods: a review
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 2406.7 |
| 2023 | 2240.7 |
| 2024 | 2316.1 |
| 2025 | 1955.8 |
Opportunities · 0219.3% of this theme group
Studies identify promising gene‑knockdown and apoptosis pathways for therapeutic development.
Apoptosis (37) · Downregulation and upregulation (57) · Gene knockdown (46) · Mutant (48)
PCBP1 binding to single-stranded poly-cytosine motifs enhances cGAS sensing and impairs breast cancer development
Modulation of ossification and inflammatory pathways during dexamethasone-induced <i>in vitro</i> osteogenesis
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0313.2% of this theme group
Papers highlight novel T‑cell and antibody strategies for treating cancers and immune disorders.
Cell culture (77) · T cell (54) · Antigen (49) · Cell (62)
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes
| Year | Share index |
|---|---|
| 2022 | 289.3 |
| 2023 | 336.1 |
| 2024 | 224.8 |
| 2025 | 204.1 |
Opportunities · 0412.8% of this theme group
Research points to new approaches for modifying DNA methylation and enhancing repair mechanisms.
DNA repair (65) · DNA damage (68) · DNA methylation (58) · DNA replication (34)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
MacroH2A-Mediated Gene Repression through Nucleosome Compaction and Remodeling Inhibition
| Year | Share index |
|---|---|
| 2022 | 224.2 |
| 2023 | 281.6 |
| 2024 | 196.5 |
| 2025 | 158.4 |
Opportunities · 0512.2% of this theme group
Works showcase fluorescent and MRI nanoparticle probes for real‑time tracking of biological processes.
In vivo (142) · Fluorescence (41) · Molecular imaging (28) · Nanotechnology (33)
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases
Recognition, Neutralization, and Clearance of Target Peptides in the Bloodstream of Living Mice by Molecularly Imprinted Polymer Nanoparticl
| Year | Share index |
|---|---|
| 2022 | 480.4 |
| 2023 | 520.5 |
| 2024 | 397.5 |
| 2025 | 406.8 |
Opportunities · 0611.7% of this theme group
Studies leverage germplasm sequencing and selection to accelerate breeding of resilient varieties.
Germplasm (37) · Selection (42) · Genetic diversity (28) · Trait (28)
Genotyping‐by‐Sequencing for Plant Breeding and Genetics
Harvesting the Promising Fruits of Genomics: Applying Genome Sequencing Technologies to Crop Breeding
| Year | Share index |
|---|---|
| 2022 | 56.0 |
| 2023 | 51.4 |
| 2024 | 46.1 |
| 2025 | 53.1 |
Opportunities · 0711.3% of this theme group
Research uncovers mRNA and microRNA modifications as key regulators of cell differentiation and disease.
Messenger RNA (103) · microRNA (61) · Transcription (65) · RNA polymerase II (34)
m <sup>6</sup> A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation
Microrna-Dependent Regulation of Dna Methyltransferase-1 and Tumor Suppressor Gene Expression by Interleukin-6 in Human Malignant Cholangioc
| Year | Share index |
|---|---|
| 2022 | 229.2 |
| 2023 | 195.8 |
| 2024 | 157.3 |
| 2025 | 136.5 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Breakthrough | 32.6% | 26.5% |
| Promising | 31.0% | 36.8% |
| Descriptive | 17.5% | 17.8% |
| Problem-identifying | 9.1% | 9.7% |
| Cautionary | 5.8% | 4.5% |
| Comparative | 2.8% | 3.7% |
| Critical | 1.3% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 18 | 0.3% | 2 (11.1%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 4 | 0.07% | 1 (25.0%) | 0.15% |
| Bias & fairnessNot All Allies Are Welcome: Partner Discrimination in Legume–Rhizobium Symbiosis | 3 | 0.05% | 1 (33.3%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 1 | 0.02% | 1 (100.0%) | 0.01% |
| Energy & datacenter footprint | 0 | 0.0% | 0 (%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.
Published patent filings in the recorded source window.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 4 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗